Asad Bashey MD

Hematology•Atlanta, GA

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Director of Clinical Research for The Blood and Marrow Transplant Program at Northside Hospital.

Join to View Full Profile

5670 Peachtree Dunwoody Rd NeSuite 1000Atlanta, GA 30342
Phone+1 404-255-1930
Fax+1 404-459-8510

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
Univ Dundee- Fac MedClass of 1984

Certifications & Licensure

CA State Medical License 1994 - 2026
GA State Medical License 2005 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Atlanta Magazine: Top Doctors Castle Connolly, 2013-2014, 2014-2022

Clinical Trials

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Start of enrollment: 2002 Dec 01
Completed
Phase 2
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2005 Jul 01
Completed
Phase 1, Phase 2
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 01
Completed
Phase 2
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Start of enrollment: 2007 Apr 01
Completed
Phase 2
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Start of enrollment: 2011 Apr 01
Completed
Phase 2
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients Start of enrollment: 2012 Feb 01
Completed
Phase 2
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
Completed
Phase 1, Phase 2
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Start of enrollment: 2013 May 16
Completed
Phase 1
Nonmyeloablative Haploidentical Transplant Followed by MLN9708 Start of enrollment: 2014 Jul 15
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies.
Piyanuch Kongtim, Pongthep Vittayawacharin, Jun Zou, Samer Srour, Brian Shaffer
Transplantation and Cellular Therapy. 2024-12-01
HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantation.
Melhem Solh, Michael T Aubrey, Xu Zhang, Asad Bashey, Brian M Freed
Bone Marrow Transplantation. 2024-10-01
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial.
Jason G Dehn, Brent Logan, Bronwen E Shaw, Steven Devine, Stefan O Ciurea
Medrxiv. 2024-09-16

Journal Articles

The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell Transplantation
Leo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature

Abstracts/Posters

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Inciden...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hemato...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Mor...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Trans...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all